Tumor necrosis factor-alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases

Acta Gastro-Enterologica Belgica

Volumn 72, Issue 2, 2009, Pages 215-221

  Hu, Zhong Wei ^a   Luo, Hong Bin ^a   Xu, Ying Min ^a   Guo, Jia Wei ^a   Deng, Xi Long ^a   Tong, Yu Wei ^a   Tang, Xiaoping ^a  

^a Guangzhou Eighth People's Hospital   (China)

Author keywords

NAFLD; NASH; TNF alpha gene polymorphism; TNF alpha protein

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650792743     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. GAEMERS I.C., GROEN A.K. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol., 2006,17 : 268-273
2. VERRIJKEN A., FRANCQUE S., VAN GAAL L. The metabolic syndrome and the liver. Acta Gastroenterol. Belg., 2008, 71: 48-59.
3. WANG J.T., LIU Y.L. Non-alcoholic fatty liver disease : the problems we are facing. Hepatobiliary Pancreat. Dis. Int., 2003, 2 : 334-337
4. MARCHESINI G., BRIZI M., MORSELLI-LABATE A.M., BIANCHI G., BUGIANESI E., MCCULLOUGH A.J., FORLANI G., MELCHIONDA N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med., 1999, 107 : 450-455
5. STREBA L.A., CARSTEA D., MITRUT P., VERE C.C., DRAGOMIR N., STREBA C.T. Nonalcoholic fatty liver disease and metabolic syndrome : a concise review. Rom. J. Morphol. Embryol., 2008, 49 : 13-20.
6. TILG H., DIEHL A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. New Engl. J. Med., 2000, 343 : 1467-1476
7. SEKI S., KITADA T., SAKAGUCHI H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol. Res., 2005, 33 : 132-134
8. HAJEER A.H., HUTCHINSON I.V. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum. Immunol., 2001, 62 : 1191-1199
9. LIO D., CANDORE G., COLOMBO A., COLONNA ROMANO G., GERVASI F., MARINO V., SCOLA L., CARUSO C. A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects : implications for autoimmunity. Hum. Immunol., 2001, 62 : 705-713
10. MARCEAU P., BIRON S., HOULD F.S., MARCEAU S., SIMARD S., THUNG S.N., KRAL J.G. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab., 1999, 84 : 1513-1517
11. PEREZ C., ALBERT I., DEFAY K., ZACHARIADES N., GOODING L., KRIEGLER M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell, 1990, 63 : 251-258 (Pubitemid 20355446)
12. BARON A.D., STEINBERG H., BRECHTEL G., JOHNSON A. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am. J. Physiol., 1994, 266 : E248-53.
13. KROEGER K.M., CARVILLE K.S., ABRAHAM L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol., 1997, 34 : 391-399
14. WILSON A.G., SYMONS J.A., MC DOWELL T.L., MC DEVITT H.O., DUFF G.W. et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA, 1997, 94 : 3195-3199
15. VALENTI L., DONGIOVANNI P., FRACANZANI A.L., SANTORELLI G., FATTA E., BERTELLI C., TAIOLI E., FIORELLI G., FARGION S. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig. Liver Dis., 2003, 35 : 172-178
16. AMERICAN GASTROENTEROLOGICAL ASSOCIATION MEDICAL POSITION STATEMENT : nonalcoholic fatty liver disease. Gastroenterology, 2002, 123 : 1702-1704
17. KLEINER DE., BRUNT E.M., VAN NATTA M., BEHLING C., CONTOS M.J., CUMMINGS OW., FERRELL L.D., LIU Y.C., TORBENSON M.S., UNALP-ARIDA A., YEH M., MC CULLOUGH A.J., SANYAL A.J. ; NONALCOHOLIC STEATOHEPATITIS CLINICAL RESEARCH NETWORK. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41 : 1313-1321 (Pubitemid 40770284)
18. ESPOSITO K., CIOTOLA M., SASSO F.C., COZZOLINO D., SACCOMANNO F., ASSALONI R., CERIELLO A., GIUGLIANO D. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome : role of tumor necrosis factor-alpha. Nutr. Metab. Cardiovasc. Dis., 2007, 17 : 274-279
19. GWOZDZIEWICZOVA S., LICHNOVSKA R., BEN YAHIA R., CHLUP R., HREBÍCEK J. TNF-alpha in the development of insulin resistance and other disorders in metabolic syndrome. Biomed. Pap. Medical Fac. Univ. Palacky, Olomouc, Czech. Repub., 2005,149 : 109-117
20. JARRAR M.H., BARANOVA A., COLLANTES R., RANARD B., STEPANOVA M., BENNETT C., FANG Y., ELARINY H., GOODMAN Z., CHANDHOKE V., YOUNOSSI Z.M. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol. Ther., 2008, 27 : 412-21.
21. XU P., ZHANG X.G., LI Y.M., YU CH., XU L., XU G.Y. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J. Zhejiang Univ. Sci. B., 2006, 7 : 627-633
22. MIDDLETON P.G., TAYLOR P.R., JACKSON G., PROCTOR S.J., DICKINSON A.M. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood, 1998, 92 : 3943-3948
23. WILSON A.G., DE VRIES N., POCIOT F., DI GIOVINE F.S., VAN DER PUTTE L.B., DUFF G.W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med., 1993, 177 : 557-560
24. ENDO M., MASAKI T., SEIKE M., YOSHIMATSU H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med. (Maywood), 2007, 232 : 614-621
25. CHEUNG O., KAPOOR A., PURI P., SISTRUN S., LUKETIC V.A., SARGEANT C.C., CONTOS M.J., SHIFFMAN M.L., STRAVITZ R.T., STERLING R.K., SANYAL A.J. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology, 2007, 46 : 1091-1100 (Pubitemid 350144773)
26. ARNER P. The adipocyte in insulin resistance : key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab., 2003, 14 : 137-145
27. MUSSO G., GAMBINO R., BIROLI G., CARELLO M., FAGÀ E., PACINI G., DE MICHIELI F., CASSADER M., DURAZZO M., RIZZETTO M., PAGANO G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2005, 100 : 2438-2446
28. UYSAL K.T., WIESBROCK S.M., MARINO M.W., HOTAMISLIGIL G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 1997, 389 : 610-614
29. KWON G., XU G., MARSHALL C.A., MC DANIEL M.L. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J. Biol. Chem., 1999, 274 : 18702-8.
30. ZUMSTEG U., FRIGERIO S., HOLLANDER G.A. Nitric oxide production and Fas surface expression mediate two independent pathways of cytokine-induced murine beta-cell damage. Diabetes, 2000, 49 : 39-47.
31. VALENTI L., FRACANZANI A.L., DONGIOVANNI P., SANTORELLI G., BRANCHI A., TAIOLI E., FIORELLI G., FARGION S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002, 122 : 274-80.